Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
The GLP-1/GLP-2 hybrid: weight loss plus gut-barrier repair was the idea; a 12-week trial did not show it.
Also known as: ZP7570 · ZP-7570
Part of the Metabolic & GLP-1 peptides cluster
Overview
Dapiglutide (ZP7570) is an investigational long-acting peptide from Zealand Pharma that activates both the GLP-1 and GLP-2 receptors, aiming to combine weight loss with improved gut barrier function and lower inflammation. In a 12-week phase 2a trial in obesity, 6 mg weekly reduced weight by 2.1% relative to placebo without reaching statistical significance, and development was paused in November 2025.
Source & context
Biological / chemical source: Synthetic peptidomimetic of the proglucagon-derived hormones GLP-1 and GLP-2
Primary research or clinical context: Investigational (Zealand Pharma) — phase 2a in obesity did not reach significance; development paused in November 2025
What dapiglutide is
Dapiglutide is a long-acting dual GLP-1 and GLP-2 receptor agonist — a peptidomimetic of the proglucagon-derived hormones GLP-1 and GLP-2 — proposed to simultaneously promote weight loss and reduce the low-grade inflammation associated with obesity and metabolic disease. It progressed to clinical trials as a once-weekly subcutaneous treatment for obesity; development was paused in November 2025 (IUPHAR ligand 14279). Its formula is C192H302N46O57 and its mass about 4,167 Da (PubChem CID 171934788).
Mechanism: two proglucagon hormones in one
GLP-1 and GLP-2 come from the same precursor but do different jobs: GLP-1 reduces food intake and improves glucose control, while GLP-2 enlarges the absorptive surface of the intestine and improves gut barrier function — the mechanism behind the approved GLP-2 analogue teduglutide for short bowel syndrome. Dapiglutide was designed to capture GLP-1 receptor-mediated weight loss together with GLP-2 receptor-mediated barrier and anti-inflammatory effects (Nielsen et al., EClinicalMedicine 2026). The GLP-2 and teduglutide profiles on this site cover the intestinal side.
Preclinical work in short bowel
In a mouse model of short bowel, dapiglutide attenuated intestinal insufficiency, with GLP-2-specific effects on absorptive surface and GLP-1-specific effects on transit characterised separately (Reiner et al., JPEN 2022), and promoted barrier function in the remnant bowel (Reiner et al., Annals of the New York Academy of Sciences 2022). That rationale — a combined GLP-1/GLP-2 agonist might enlarge intestinal surface area while slowing transit — remains a plausible short-bowel application even though the obesity programme stalled.
Phase 2a in obesity
An investigator-initiated, 12-week, double-blind, placebo-controlled proof-of-concept trial in Denmark randomised 54 adults with obesity (mean BMI 35.2) to once-weekly dapiglutide 4 or 6 mg or placebo without lifestyle intervention. In the primary analysis, 6 mg produced a mean weight change of −2.1% relative to placebo (95% CI −4.3 to 0.2; p=0.076) — not statistically significant. Dapiglutide appeared safe and well tolerated, with reduced appetite and nausea the common adverse events and no discontinuations for drug-related events; the authors suggested higher doses in larger, longer studies (Nielsen et al., 2026).
| Arm | Weight change vs placebo | Dropout |
|---|---|---|
| Placebo | — | 0% |
| Dapiglutide 4 mg weekly | Not significant | 11% |
| Dapiglutide 6 mg weekly | −2.1% (p=0.076) | 6% |
Status
ClinicalTrials.gov lists two studies as of September 2026 — the Copenhagen phase 2 trial (NCT05788601) and a completed phase 1 formulation study (NCT06758583). With development paused, dapiglutide's main value is as a test of the GLP-1/GLP-2 hypothesis: at the doses and duration studied, adding GLP-2 activity did not deliver GLP-1-class weight loss.
What this page is not
Dapiglutide is investigational, not approved anywhere, and not in active development as of the IUPHAR record. Anything sold under the name is unlicensed; this profile is educational and not guidance on obtaining or using it.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Peptidomimetic of GLP-1 and GLP-2, engineered for once-weekly subcutaneous dosing
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C192H302N46O57
- Average reference mass
- ≈ 4,167
- Receptors
- GLP-1 receptor and GLP-2 receptor — dual agonist
- Backbone
- Peptidomimetic of GLP-1 and GLP-2, engineered for once-weekly subcutaneous dosing
- Status
- Investigational; development paused November 2025 (IUPHAR record). Not approved anywhere
Chemistry values: curated profile, PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 2 registered studies with “Dapiglutide” as an intervention (snapshot 2026-09-07). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT06758583 | A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide | Phase 1 | completed | 2025-05-06 |
| NCT05788601 | Dapiglutide for the Treatment of Obesity | Phase 2 | active not recruiting | 2024-12-05 |
Dapiglutide — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Peptidomimetic of GLP-1 and GLP-2, engineered for once-weekly subcutaneous dosingAverage reference mass: 4,167 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
Change log
Dated observations from the data pipeline (registry flags, trial footprints, identifiers) and editorial reviews of this profile.
- IdentifiersCross-linked to IUPHAR ligand 14279 and PubChem CID 171934788.
- TrialsClinicalTrials.gov snapshot added: 2 registered studies, highest phase 2.
- EditorialProfile content reviewed and updated by the editorial team.
FAQ about Dapiglutide
What is Dapiglutide?+
Dapiglutide (ZP7570) is an investigational long-acting peptide from Zealand Pharma that activates both the GLP-1 and GLP-2 receptors, aiming to combine weight loss with improved gut barrier function and lower inflammation. In a 12-week phase 2a trial in obesity, 6 mg weekly reduced weight by 2.1% relative to placebo without reaching statistical significance, and development was paused in November 2025.
What Canadian product status is recorded for Dapiglutide?+
Canadian product status for Dapiglutide has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Dapiglutide?+
Dapiglutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
What is dapiglutide?+
ZP7570, an investigational Zealand Pharma peptide that activates both GLP-1 and GLP-2 receptors, intended to combine weight loss with gut-barrier and anti-inflammatory effects.
Did dapiglutide work for weight loss?+
In a 12-week phase 2a trial, 6 mg weekly reduced weight by 2.1% relative to placebo, which was not statistically significant (p=0.076).
Is dapiglutide still in development?+
Development was paused in November 2025 according to the IUPHAR record.
What is the difference between GLP-1 and GLP-2?+
Both come from proglucagon; GLP-1 reduces food intake and improves glucose control, while GLP-2 promotes intestinal growth and barrier function (the basis of teduglutide for short bowel syndrome).
Related peptides
References & further reading
- 1.Nielsen et al. (2026). Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial. EClinicalMedicine
- 2.Reiner et al. (2022). The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel. Annals of the New York Academy of Sciences
- 3.Reiner et al. (2022). Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. JPEN Journal of Parenteral and Enteral Nutrition
- 4.PubChem — compound summary for Dapiglutide (CID 171934788)